Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance

What Was Tested

This clinical trial paper looks at Exenatide and Insulin Glargine in the context of insulin resistance, prediabetes & type 2 diabetes.

Who Took Part

According to the abstract, 2 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washout treatment of metformin, 6-month exenatide treatment, and 6-month glargine treatment were administrated sequentially accompanied with previous metformin.

How the Study Was Run

Glucolipid metabolic parameters were compared among groups.

Adipose distribution was quantified with computerized tomography according to anatomy, dividing into visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), adding up to total adipose tissue (TAT).

What Was Measured

Topics PubMed links to this paper include Adiposity, Blood Glucose, Body Fat Distribution, Diabetes Mellitus, Type 2, Exenatide, Insulin Glargine and Insulin Resistance.

What This Means in Plain Language

This is a clinical trial of Exenatide and Insulin Glargine in 2 patients in people with insulin resistance, prediabetes & type 2 diabetes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Journal of diabetes research), a journal based in United States.

More context: the Exenatide compound page and the Insulin Glargine compound page, Insulin resistance, prediabetes & type 2 diabetes research.